• Ignite Proteomics, precision oncology subsidiary of Aditxt, was featured in a peer-reviewed Dana-Farber study in npj Precision Oncology on biomarker prediction for trastuzumab deruxtecan (Enhertu) in metastatic breast cancer.
• Study found standard HER2 IHC often had limited predictive value in matched biomarker sub-cohorts, while Ignite’s RPPA multiplex assay showed predictive value for patient outcomes.
• Results highlighted TOPO1 expression detectable by Ignite’s platform in some HER2-negative patients, supporting a broader biomarker approach beyond HER2 status for treatment selection.
• Ignite’s RPPA assay is CLIA-certified, CAP-accredited, listed under AMA CPT PLA 0249U, and orderable on standard biopsy tissue.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ADiTx Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202604200815BIZWIRE_USPR_____20260420_BW307974) on April 20, 2026, and is solely responsible for the information contained therein.